Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by LCM Capital Management Inc

LCM Capital Management Inc boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 486 shares of the biopharmaceutical company’s stock after purchasing an additional 12 shares during the period. LCM Capital Management Inc’s holdings in Regeneron Pharmaceuticals were worth $427,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently added to or reduced their stakes in REGN. Valeo Financial Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 20.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 619 shares of the biopharmaceutical company’s stock worth $509,000 after buying an additional 103 shares in the last quarter. Atlantic Union Bankshares Corp increased its holdings in shares of Regeneron Pharmaceuticals by 17.3% during the third quarter. Atlantic Union Bankshares Corp now owns 1,106 shares of the biopharmaceutical company’s stock valued at $910,000 after purchasing an additional 163 shares during the period. PDS Planning Inc raised its stake in shares of Regeneron Pharmaceuticals by 8.3% during the third quarter. PDS Planning Inc now owns 338 shares of the biopharmaceutical company’s stock valued at $278,000 after purchasing an additional 26 shares in the last quarter. Accurate Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter worth about $229,000. Finally, Cambridge Investment Research Advisors Inc. grew its position in Regeneron Pharmaceuticals by 135.8% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 10,126 shares of the biopharmaceutical company’s stock valued at $8,333,000 after buying an additional 5,832 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.2 %

NASDAQ:REGN traded down $1.82 during trading hours on Tuesday, hitting $890.66. 627,942 shares of the company’s stock traded hands, compared to its average volume of 491,369. The stock’s fifty day moving average price is $945.77 and its two-hundred day moving average price is $895.19. The firm has a market cap of $97.76 billion, a P/E ratio of 25.63, a P/E/G ratio of 2.54 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $10.96 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the transaction, the director now directly owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,195 shares of company stock valued at $9,759,898. Insiders own 8.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. TD Cowen boosted their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Bank of America upped their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. Finally, BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.